Showing results (41-50 of 610) with videos related to
Sort By:
Pageof 61
Targeted Oncology|August 28, 2015
First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid TumorsRodrigo Dienstmann, Ulrik Lassen, Jonathan Cebon, et al.Scientific Reports|September 21, 2019
Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancerGarazi Serna, Fiorella Ruiz-Pace, Fabiola Cecchi, et al.Oncotarget|March 30, 2011
Personalizing therapy with targeted agents in non-small cell lung cancerRodrigo Dienstmann, Pablo Martinez, Enriqueta FelipEuropean Journal of Cancer (Oxford, England : 1990)|October 4, 2023
Clinical and genomic characterisation of early-onset pancreatic cancerFlorian Castet, Carles Fabregat-Franco, Gloria Castillo, et al.Expert Opinion on Biological Therapy|August 26, 2014
Evaluation of aflibercept in the treatment of metastatic colorectal cancerTeresa Macarulla, Tamara Sauri, Josep TaberneroSeminars in Oncology|November 29, 2015
Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid TumorsCinta Hierro, Jordi Rodon, Josep TaberneroClinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2014
Paracrine network: another step in the complexity of resistance to EGFR blockade?Ramon Salazar, Gabriel Capellà, Josep TaberneroThe Oncologist|February 29, 2008
Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?Josep Tabernero, Per Pfeiffer, Andrés CervantesAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 3, 2022
The Evolving Treatment Landscape in BRAF-V600E-Mutated Metastatic Colorectal CancerJosep Tabernero, Javier Ros, Elena ÉlezCurrent Treatment Options in Oncology|September 17, 2015
First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405Elena Elez, Guillem Argilés, Josep TaberneroPageof 61